The smart targeting of nanoparticles

Current Pharmaceutical Design

Volumn 19, Issue 35, 2013, Pages 6315-6329

  Friedman, Adam D ^a   Claypool, Sarah E ^a   Liu, Rihe ^a  

^a University of North Carolina   (United States)

Author keywords

Antibody; Aptamer; Chimera; Conjugation; Ligand; Multivalent; Nanomedicine; Nanoparticle; Peptide; Protein domain; Small molecule; Targeting

Indexed keywords

29D7; AB 76586; AB 84231; ADALIMUMAB; ANTIBODY; APTAMER; ATCC 27660; BETA CYCLODEXTRIN; CETUXIMAB; CHITOSAN; DENDRIMER; E 2156; FIB 504; FOLIC ACID; GOLD NANOPARTICLE; GRAPHITE; LIGAND; LIPOSOME; MONOCLONAL ANTIBODY 35; MONOCLONAL ANTIBODY 37; MONOCLONAL ANTIBODY 4G6; MONOCLONAL ANTIBODY 62; MONOCLONAL ANTIBODY GI34; MYRISTIC ACID; NANOPARTICLE; NCM 460; NUCLEIC ACID; PANITUMUMAB; PEGAPTANIB; PEPTIDE DERIVATIVE; POLY(METHYL METHACRYLATE); POLYANHYDRIDE; POLYGLACTIN; POLYSTYRENE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

COLORECTAL CANCER; COVALENT BOND; DISULFIDE BOND; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; HUMAN; LIGAND BINDING; NANOMEDICINE; NONHUMAN; PARTICLE SIZE; PHAGE DISPLAY; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN ENGINEERING; REVIEW; RHEUMATOID ARTHRITIS;

ANIMALS; DRUG DELIVERY SYSTEMS; DRUG DESIGN; HUMANS; LIGANDS; NANOMEDICINE; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; TISSUE DISTRIBUTION;

EID: 84887984349     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/13816128113199990375     Document Type: Review

References (103)

1. Liu R, Kay BK, Jiang S, Chen S. Nanoparticle Delivery: Targeting and Nonspecific Binding. MRS Bulletin 2009; 34(6): 432-40.
2. Kiick KL, Saxon E, Tirrell DA, Bertozzi CR. Incorporation of azides into recombinant proteins for chemoselective modification by the Staudinger ligation. Proc Natl Acad Sci USA 2002; 99(1): 19-24.
3. Johnson JA, Lu YY, Van Deventer JA, Tirrell DA. Residuespecific incorporation of non-canonical amino acids into proteins: recent developments and applications. Curr Opinion Chem Biol 2010; 14(6): 774-80.
4. Liu CC, Mack AV, Tsao ML, et al. Protein evolution with an expanded genetic code. Proc Natl Acad Sci USA 2008; 105(46): 17688-93.
5. Algar WR, Prasuhn DE, Stewart MH, et al. The controlled display of biomolecules on nanoparticles: a challenge suited to bioorthogonal chemistry. Bioconjugate Chem 2011; 22(5): 825-58.
6. Los GV, Wood K. The HaloTag: a novel technology for cell imaging and protein analysis. Methods Mol Biol 2007; 356: 195-208.
7. Hodneland CD, Lee YS, Min DH, Mrksich M. Selective immobilization of proteins to self-assembled monolayers presenting active site-directed capture ligands. Proc Natl Acad Sci USA 2002; 99(8): 5048-52.
8. Jongsma MA, Litjens RH. Self-assembling protein arrays on DNA chips by auto-labeling fusion proteins with a single DNA address. Proteomics 2006; 6(9): 2650-5.
9. Low Ps, Henne Wa, Doorneweerd Dd. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 2008; 41(1): 120-9.
10. Zhao X, Li H, Lee Rj. Targeted drug delivery via folate receptors. Expert Opin Drug Deliv 2008; 5(3): 309-19.
11. Mach RH, Huang Y, Freeman RA, Wu L, Vangveravong S, Luedtke RR. Conformationally-flexible benzamide analogues as dopamine D3 and sigma 2 receptor ligands. Bioorganic Med Chem Letters 2004; 14(1): 195-202.
12. Banerjee R, Tyagi P, Li S, Huang L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 2004; 112(4): 693-700.
13. Cruz LJ, Tacken PJ, Pots JM, Torensma R, Buschow SI, Figdor CG. Comparison of antibodies and carbohydrates to target vaccines to human dendritic cells via DC-SIGN. Biomaterials 2012; 33(16): 4229-39.
14. Kozikowski Ap, Nan F, Conti P, et al. Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J Med Chem 2001; 44(3): 298-301.
15. Kozikowski Ap, Zhang J, Nan F, et al. Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem 2004; 47(7): 1729-38.
16. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009; 13(3): 256-62.
17. Liao D, Liu Z, Wrasidlo W, et al. Synthetic enzyme inhibitor: a novel targeting ligand for nanotherapeutic drug delivery inhibiting tumor growth without systemic toxicity. Nanomed: Nanotechnol, Biol, Med 2011; 7(6): 665-73.
18. Chandran Ss, Banerjee Sr, Mease Rc, Pomper Mg, Denmeade Sr. Characterization of a targeted nanoparticle functionalized with a urea-based inhibitor of prostate-specific membrane antigen (PSMA). Cancer Biol Ther 2008; 7(6): 974-82.
19. Banerjee Sr, Foss Ca, Castanares M, et al. Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostatespecific membrane antigen (PSMA). J Med Chem 2008; 51(15): 4504-17.
20. Humblet V, Misra P, Bhushan Kr, et al. Multivalent Scaffolds for Affinity Maturation of Small Molecule Cell Surface Binders and Their Application to Prostate Tumor Targeting. J Med Chem 2008; 24: 24.
21. Li J, Gu B, Meng Q, Yan Z, Gao H, Chen X, et al. The use of myristic acid as a ligand of polyethylenimine/DNA nanoparticles for targeted gene therapy of glioblastoma. Nanotechnology 2011; 22(43): 435101.
22. Nie G, Hah HJ, Kim G, et al. Hydrogel nanoparticles with covalently linked coomassie blue for brain tumor delineation visible to the surgeon. Small 2012; 8(6): 884-91.
23. Liu T, Li X, Qian Y, Hu X, Liu S. Multifunctional pH-disintegrable micellar nanoparticles of asymmetrically functionalized betacyclodextrin-based star copolymer covalently conjugated with doxorubicin and DOTA-Gd moieties. Biomaterials 2012; 33(8): 2521-31.
24. Couvreur P, Kante B, Lenaerts V, Scailteur V, Roland M, Speiser P. Tissue distribution of antitumor drugs associated with polyalkylcyanoacrylate nanoparticles. J Pharm Sci 1980; 69(2): 199-202.
25. Kreuter J, Hartmann HR. Comparative study on the cytostatic effects and the tissue distribution of 5-fluorouracil in a free form and bound to polybutylcyanoacrylate nanoparticles in sarcoma 180-bearing mice. Oncology 1983; 40(5): 363-6.
26. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228(4705): 1315-7.
27. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256(5517): 495-7.
28. Vaughan TJ, Williams AJ, Pritchard K, et al. Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library. Nat Biotechnol 1996; 14(3): 309-14.
29. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis and rheumatism 2003; 48(1): 35-45.
30. Russell ND, Corvalan JR, Gallo ML, Davis CG, Pirofski L. Production of protective human antipneumococcal antibodies by transgenic mice with human immunoglobulin loci. Infection Immunity 2000; 68(4): 1820-6.
31. Lonberg N. Human antibodies from transgenic animals. Nat Biotechnol 2005; 23(9): 1117-25.
32. Chua YJ, Cunningham D. Panitumumab. Drugs Today (Barc) 2006; 42(11): 711-9.
33. Reichert JM, Valge-Archer VE. Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 2007; 6(5): 349-56.
34. Popov J, Kapanen AI, Turner C, et al. Multivalent rituximab lipid nanoparticles as improved lymphoma therapies: indirect mechanisms of action and in vivo activity. Nanomedicine (Lond) 2011; 6(9): 1575-91.
35. Deepagan VG, Sarmento B, Menon D, et al. In vitro targeted imaging and delivery of camptothecin using cetuximab-conjugated multifunctional PLGA-ZnS nanoparticles. Nanomedicine (Lond) 2012; 7(4): 507-19.
36. Yang K, Zhang FJ, Tang H, et al. In-vivo imaging of oral squamous cell carcinoma by EGFR monoclonal antibody conjugated near-infrared quantum dots in mice. Int J Nanomed 2011; 6: 1739-45.
37. Liu X, Wang Y, Hnatowich DJ. A nanoparticle for tumor targeted delivery of oligomers. Methods Mol Biol 2011; 764: 91-105.
38. Ding B, Wu X, Fan W, et al. Anti-DR5 monoclonal antibodymediated DTIC-loaded nanoparticles combining chemotherapy and immunotherapy for malignant melanoma: target formulation development and in vitro anticancer activity. Int J Nanomed 2011; 6: 1991-2005.
39. Chikkaveeraiah BV, Solda A, Choudhary D, Maran F, Rusling JF. Ultrasensitive nanostructured immunosensor for stem and carcinoma cell pluripotency gatekeeper protein NANOG. Nanomedicine (Lond) 2012; 7(7): 957-65.
40. Deutscher SL. Phage display in molecular imaging and diagnosis of cancer. Chem Rev 2010; 110(5): 3196-211.
41. Kehoe JW, Kay BK. Filamentous phage display in the new millennium. Chem Rev 2005; 105(11): 4056-72.
42. Han M, Kickhoefer VA, Nemerow GR, Rome LH. Targeted vault nanoparticles engineered with an endosomolytic peptide deliver biomolecules to the cytoplasm. ACS nano 2011; 5(8): 6128-37.
43. Sandoval MA, Sloat BR, Lansakara PD, et al. EGFR-targeted stearoyl gemcitabine nanoparticles show enhanced anti-tumor activity. J controlled release: official J Controlled Release Soc 2012; 157(2): 287-96.
44. Liu Y, Pressly ED, Abendschein DR, et al. Targeting angiogenesis using a C-type atrial natriuretic factor-conjugated nanoprobe and PET. J nuclear medicine: official publication, Soc Nuclear Med 2011; 52(12): 1956-63.
45. Xin H, Sha X, Jiang X, et al. The brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(epsiloncaprolactone) nanoparticles. Biomaterials 2012; 33(5): 1673-81.
46. Scari G, Porta F, Fascio U, et al. Gold nanoparticles capped by a GC-containing peptide functionalized with an RGD motif for integrin targeting. Bioconjugate Chem 2012; 23(3): 340-9.
47. Ming X, Feng L. Targeted delivery of a splice-switching oligonucleotide by cationic polyplexes of RGD-oligonucleotide conjugate. Mol Pharma 2012; 9(5): 1502-10.
48. Zhou A, Wei Y, Wu B, Chen Q, Xing D. Pyropheophorbide A and c(RGDyK) comodified chitosan-wrapped upconversion nanoparticle for targeted near-infrared photodynamic therapy. Mol Pharm 2012; 9(6): 1580-9. Epub 2012/04/27.
49. Lv PP, Ma YF, Yu R, et al. Targeted delivery of insoluble cargo (paclitaxel) by PEGylated chitosan nanoparticles grafted with Arg-Gly-Asp (RGD). Molecular pharmaceutics 2012; 9(6): 1736-47.
50. Zhang F, Huang X, Zhu L, Guo N, Niu G, Swierczewska M, et al. Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials 2012; 33(21): 5414-22.
51. Wadajkar AS, Bhavsar Z, Ko CY, et al. Multifunctional particles for melanoma-targeted drug delivery. Acta biomaterialia 2012; 8(8): 2996-3004.
52. Koczulla AR, Bals R. Antimicrobial peptides: current status and therapeutic potential. Drugs 2003; 63(4): 389-406.
53. Bradshaw J. Cationic antimicrobial peptides: issues for potential clinical use. BioDrugs: clinical immunotherapeutics, biopharmaceuticals and gene therapy 2003; 17(4): 233-40.
54. Yeaman MR, Yount NY. Mechanisms of antimicrobial peptide action and resistance. Pharmacological Rev 2003; 55(1): 27-55.
55. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993; 363(6428): 446-8.
56. Muyldermans S, Atarhouch T, Saldanha J, Barbosa Ja, Hamers R. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng 1994; 7(9): 1129-35.
57. Desmyter A, Transue TR, Ghahroudi MA, et al. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat Struct Biol 1996; 3(9): 803-11.
58. Martin F, Volpari C, Steinkuhler C, et al. Affinity selection of a camelized V(H) domain antibody inhibitor of hepatitis C virus NS3 protease. Protein Eng 1997; 10(5): 607-14.
59. Reiter Y, Schuck P, Boyd LF, Plaksin D. An antibody singledomain phage display library of a native heavy chain variable region: isolation of functional single-domain VH molecules with a unique interface. J Mol Biol 1999; 290(3): 685-98.
60. Riechmann L, Muyldermans S. Single domain antibodies: comparison of camel VH and camelised human VH domains. J Immunol Methods 1999; 231(1-2): 25-38.
61. Muyldermans S. Single domain camel antibodies: current status. J Biotechnol 2001; 74(4): 277-302.
62. Conrath Ke, Lauwereys M, Galleni M, et al. Beta-lactamase inhibitors derived from single-domain antibody fragments elicited in the camelidae. Antimicrob Agents Chemother 2001; 45(10): 2807-12.
63. Desmyter A, Decanniere K, Muyldermans S, Wyns L. Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem 2001; 276(28): 26285-90.
64. Holt Lj, Herring C, Jespers Ls, Woolven Bp, Tomlinson Im. Domain antibodies: proteins for therapy. Trends Biotechnol 2003; 21(11): 484-90.
65. Chen W, Zhu Z, Feng Y, Xiao X, Dimitrov Ds. Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identified highly soluble, stable heavy chain variable domain. J Mol Biol 2008; 382(3): 779-89.
66. Chen W, Zhu Z, Feng Y, Dimitrov Ds. Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci U S A 2008; 105(44): 17121-6.
67. Nygren PA, Uhlen M. Scaffolds for engineering novel binding sites in proteins. Curr Opin Struct Biol 1997; 7(4): 463-9.
68. Pessi A, Bianchi E, Crameri A, Venturini S, Tramontano A, Sollazzo M. A designed metal-binding protein with a novel fold. Nature 1993; 362(6418): 367-9.
69. Martin F, Toniatti C, Salvati AL, et al. The affinity-selection of a minibody polypeptide inhibitor of human interleukin-6. Embo J 1994; 13(22): 5303-9.
70. McConnell SJ, Hoess RH. Tendamistat as a scaffold for conformationally constrained phage peptide libraries. J Mol Biol 1995; 250(4): 460-70.
71. Skerra A. Engineered protein scaffolds for molecular recognition. J Mol Recognit 2000; 13(4): 167-87.
72. Binz Hk, Pluckthun A. Engineered proteins as specific binding reagents. Curr Opin Biotechnol 2005; 16(4): 459-69.
73. Binz Hk, Amstutz P, Pluckthun A. Engineering novel binding proteins from nonimmunoglobulin domains. Nat Biotechnol 2005; 23(10): 1257-68.
74. Skerra A. Alternative non-antibody scaffolds for molecular recognition. Curr Opin Biotechnol 2007; 18(4): 295-304.
75. Wilson DS, Szostak JW. In vitro selection of functional nucleic acids. Annu Rev Biochem 1999; 68: 611-47.
76. Tuerk C, Gold L. Systematic evolution of ligands by exponential enrichment: RNA ligands to bacteriophage T4 DNA polymerase. Science 1990; 249(4968): 505-10.
77. Daniels Da, Chen H, Hicke Bj, Swiderek Km, Gold L. A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A 2003; 100(26): 15416-21.
78. Shangguan D, Li Y, Tang Z, et al. Aptamers evolved from live cells as effective molecular probes for cancer study. Proc Natl Acad Sci U S A 2006; 103(32): 11838-43.
79. de Campos WRL, Coopusamy D, Morris L, Mayosi BM, Khati M. Cytotoxicological Analysis of a gp120 Binding Aptamer with Cross-Clade Human Immunodeficiency Virus Type 1 Entry Inhibition Properties: Comparison to Conventional Antiretrovirals. Antimicrob Agents Chemother 2009; 53(7): 3056-64.
80. Group TES. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration. Retina 2002; 22(2): 143-52.
81. Group TES. Anti-vascular endothelial growth factor therapy for subfoveal choroidal neovascularization secondary to age-related macular degeneration: Phase II study results. Ophthalmology 2003; 110(5): 979-86.
82. Pagratis NC, Bell C, Chang YF, et al. Potent 2[prime]-amino-, and 2[prime]-fluoro-2[prime]-deoxyribonucleotide RNA inhibitors of keratinocyte growth factor 1997; 15(1): 68-73.
83. Jayasena SD. Aptamers: An Emerging Class of Molecules That Rival Antibodies in Diagnostics. Clin Chem 1999; 45(9): 1628-50.
84. Khati M. The future of aptamers in medicine. J Clinical Pathology 2010; 63(6): 480-7.
85. White RR, Shan S, Rusconi CP, et al. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proceedings of the National Academy of Sciences 2003; 100(9): 5028-33.
86. Pieken W, Olsen D, Benseler F, Aurup H, Eckstein F. Kinetic characterization of ribonuclease-resistant 2'-modified hammerhead ribozymes. Science 1991; 253(5017): 314-7.
87. Bell C, Lynam E, Landfair D, Janjic N, Wiles M. Oligonucleotide NX1838 inhibits VEGF165-mediated cellular responses in vitro. In vitro Cellular & Developmental Biology-Animal 1999; 35(9): 533-42.
88. Seferos DS, Prigodich AE, Giljohann DA, Patel PC, Mirkin CA. Polyvalent DNA nanoparticle conjugates stabilize nucleic acids. Nano letters 2009; 9(1): 308-11.
89. Giljohann DA, Seferos DS, Prigodich AE, Patel PC, Mirkin CA. Gene regulation with polyvalent siRNA-nanoparticle conjugates. J Am Chem Soc 2009; 131(6): 2072-3.
90. Lee IH, An S, Yu MK, Kwon HK, Im SH, Jon S. Targeted chemoimmunotherapy using drug-loaded aptamer-dendrimer bioconjugates. J controlled release: official J Controlled Release Soc 2011; 155(3): 435-41.
91. Yu MK, Kim D, Lee IH, So JS, Jeong YY, Jon S. Image-guided prostate cancer therapy using aptamer-functionalized thermally cross-linked superparamagnetic iron oxide nanoparticles. Small 2011; 7(15): 2241-9.
92. Bhattacharyya S, Khan JA, Curran GL, Robertson JD, Bhattacharya R, Mukherjee P. Efficient delivery of gold nanoparticles by dual receptor targeting. Adv Mater 2011; 23(43): 5034-8.
93. Kluza E, Jacobs I, Hectors SJ, et al. Dual-targeting of alphavbeta3 and galectin-1 improves the specificity of paramagnetic/fluorescent liposomes to tumor endothelium in vivo. J controlled release: official J Controlled Release Soc 2012; 158(2): 207-14.
94. Ko HY, Choi KJ, Lee CH, Kim S. A multimodal nanoparticlebased cancer imaging probe simultaneously targeting nucleolin, integrin alphavbeta3 and tenascin-C proteins. Biomaterials 2011; 32(4): 1130-8.
95. Basel MT, Shrestha TB, Troyer DL, Bossmann SH. Proteasesensitive, polymer-caged liposomes: a method for making highly targeted liposomes using triggered release. ACS nano 2011; 5(3): 2162-75.
96. Kennedy LC, Bear AS, Young JK, et al. T cells enhance gold nanoparticle delivery to tumors in vivo. Nanoscale Res Letters 2011; 6(1): 283.
97. Cho HR, Choi SH, Lee N, Hyeon T, Kim H, Moon WK. Macrophages homing to metastatic lymph nodes can be monitored with ultrasensitive ferromagnetic iron-oxide nanocubes and a 1. 5T clinical MR scanner. PloS one 2012; 7(1): e29575.
98. Smith GP. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 1985; 228(4705): 1315-7.
99. Lindqvist BH, Naderi S. Peptide presentation by bacteriophage P4. FEMS microbiology reviews 1995; 17(1-2): 33-9.
100. Sternberg N, Hoess RH. Display of peptides and proteins on the surface of bacteriophage lambda. Proc Natl Acad Sci USA 1995; 92(5): 1609-13.
101. Santini C, Brennan D, Mennuni C, et al. Efficient display of an HCV cDNA expression library as C-terminal fusion to the capsid protein D of bacteriophage lambda. J Mol Biol 1998; 282(1): 125-35.
102. Hashemi H, Pouyanfard S, Bandehpour M, et al. Immunization with M2e-displaying T7 bacteriophage nanoparticles protects against influenza A virus challenge. PloS one 2012; 7(9): e45765. Epub 2012/10/03.
103. Lee JH, Domaille DW, Cha JN. Amplified protein detection and identification through DNA-conjugated M13 bacteriophage. ACS nano 2012; 6(6): 5621-6.